NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00643201,Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism,https://clinicaltrials.gov/study/NCT00643201,,COMPLETED,"The purpose of this study is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients with deep vein thrombosis (DVT) or pulmonary embolism (PE)",YES,Venous Thrombosis,DRUG: Enoxaparin|DRUG: warfarin|DRUG: Placebo for apixaban|DRUG: Placebo for enoxaparin|DRUG: Placebo for warfarin|DRUG: apixaban,"Incidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment, VTE: nonfatal deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE). All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants): n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint: events at any time from randomization until end of intended treatment, regardless whether drug treatment was received. All randomized participants with a non-missing primary endpoint were summarized. Missing endpoint = outcomes which could not be documented on or after study Day 154. Participants were categorized to the assigned group regardless of the treatment actually received (intent-to-treat)., Day 1 to Week 24 + 2 Days or 355 days (Discontinued Early)","Incidence of Adjudicated Composite of Recurrent Symptomatic Venous Thromboembolism (VTE) or All-Cause Death, VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie intent to treat (ITT) principle. Each participant scored as having an event only if they experienced one or more of the elements of the composite. Participants with missing endpoint information excluded., Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)|Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or Cardiovascular (CV)-Related Death, VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants, participants with missing endpoint information excluded). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie, ITT principle. Each participant scored as having an event only if the participant experienced one or more of the elements of the composite., Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)|Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or VTE-related Death or Major Bleeding, VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major bleeding defined by International Society on Thrombosis and Haemostasis: acute, clinically overt bleeding associated with decrease in hemoglobin (Hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or bleeding that is fatal . Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period. Events included regardless of whether or not participant received treatment, ie, ITT principle, Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)|Incidence of Adjudicated Composite of Recurrent Symptomatic VTE, Myocardial Infarction, Stroke, CV-related Death, Clinically Relevant Non-major (CRNM) Bleeding or Major Bleeding, VTE=Nonfatal DVT or nonfatal PE adjudicated by ICAC blinded to treatment. DVT: compression ultrasound and/or venography; PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major Bleeding = acute, clinically overt bleeding: decrease in Hgb of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis \>5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period). Events included regardless of whether or not treatment was received (ITT)., Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)|Incidence of Adjudicated Symptomatic Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period, DVT adjudicated by an ICAC blinded to treatment. DVT evaluated by: compression ultrasound and/or venography. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication, intent to treat principle (ITT). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early)., Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)|Incidence of Adjudicated Symptomatic Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period, PE adjudicated by an ICAC blinded to treatment. PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early)., Day 1 to Week 24 + + 2 Days or 355 Days (Discontinued Early)|Incidence of Adjudicated Venous Thromboembolism (VTE)-Related Death During the Intended Treatment Period, VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle)., Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)|Incidence of Cardiovascular (CV)-Related Death Including VTE-related Death During the Intended Treatment Period, VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle)., Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)|Incidence of All-Cause Death During the Intended Treatment Period, Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint information)., Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)|Incidence of Adjudicated Major Bleeding During the Treatment Period in Treated Participants, All events were adjudicated by an ICAC blinded to treatment. Bleeding defined by International Society on Thrombosis and Haemostasis: Major Bleeding: acute, clinically overt bleeding: decrease in hemoglobin (hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received., Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)|Incidence of Adjudicated Major/CRNM Bleeding During the Treatment Period in Treated Participants, Major Bleeding = acute, clinically overt bleeding: decrease in hemoglobin of 2 g/dL or more, or bleeding leading to transfusion, or bleeding in a critical site, or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis \>5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. Minor =: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events were adjudicated by an ICAC blinded to treatment. Total bleeding = any of major, or CRNM, or minor bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of treated (received at least 1 dose of study drug)., Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)|Incidence of Adjudicated Clinically Relevant Non Major (CRNM) Bleeding During the Treatment Period in Treated Participants, Bleeding defined by International Society on Thrombosis and Haemostasis: CRNM defined as acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis \>5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received., Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)|Incidence of Adjudicated Minor Bleeding During the Treatment Period in Treated Participants, Bleeding defined by International Society on Thrombosis and Haemostasis: Minor bleeding: all acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events wre adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants) calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received., Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)|Incidence of Adjudicated Total Bleeding During the Treatment Period in Treated Participants, Bleeding defined by International Society on Thrombosis and Haemostasis: Total Bleeding defined as any of major, CRNM, or minor bleeding. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received., Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)|Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Bleeding AEs, Discontinuations Due to AEs and Death During the Treatment Period in Treated Participants, Treated Participants: all who received at least 1 dose of study drug. Participants categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to treatment received. Included all SAEs and AEs with onset from first dose to last dose + 2 days (for AEs) or + 30 days (for SAEs); note; bleeding AEs and SAEs from first dose to last dose + 2 days included. Discontinuations due to AE included all AEs/SAEs from first dose until drug was discontinued. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization., First dose to last dose of 24 Weeks + 2 days (AEs) or + 30 days (SAEs) or until drug discontinued|Number of Treated Participants With Marked Abnormalities in Hematology Laboratory Tests, Lower limit of normal (LLN). Upper limit of normal (ULN). Pre-therapy (PreRx). Absolute (Abs) neutrophil count, bands + neutrophils (ANC). Cells per microliter (c/µL). Grams per deciliter (g/dL). Cells per Liter (c/L). Millimeter (MM). White blood cells: \< 0.75\*LLN, \> 1.25\*ULN; Hemoglobin: \<= 11.5 g/dL (males), \<= 9.5 g/dL (females); Hematocrit: \<= 37% (males), \<= 32% (females); Erythrocytes: \<0.75\*10\^6 c/µL\*PreRx; Platelet count: \< 75\*10\^9 c/L, \> 700\*10\^9 c/L; ANC: \< 1.00\*10\^3 c/µL; Abs eosinophils: \> 0.750\*10\^3 c/µL; Abs Basophils: \> 400/MM\^3; Abs Monocytes\> 2000/MM\^3; Abs Lymphocytes: \< 0.750\*10\*3 c/ µL, \> 7.5\*10\^3 c/ µL., Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)|Number of Treated Participants With Marked Abnormalities in Electrolyte Laboratory Tests, Bicarbonate milliequivalents/Liter (mEq/L) Low/High: \< 0.75\*LLN or \> 1.25\*ULN, or if pre-dose \< LLN then use \< 0.75\*pre-dose or \> ULN if pre-dose \> ULN then use \> 1.25\*pre-dose or \< LLN; Serum Calcium mg/dL Low/High: \< 0.8\*LLN or \> 1.2\*ULN, or if pre-dose \< LLN then use \< 0.75\*pre-dose or \> ULN if pre-dose \> ULN then use \> 1.25\*pre-dose or \< LLN; Serum Chloride mEq/L: \< 0.9\*LLN or \> 1.1\*ULN, or if pre-dose \< LLN then use \< 0.9\*pre-dose or \> ULN if pre-dose \> ULN then use \> 1.1\*pre-dose or \< LLN; Serum Potassium mEq/L: \< 0.9\*LLN or \> 1.1\*ULN, or if pre-dose \< LLN then use \< 0.9\*pre-dose or \> ULN if pre-dose \> ULN then use \> 1.1\*pre-dose or \< LLN; Serum Sodium mEq/L: \< 0.95\*LLN or \> 1.05\*ULN, or if pre-dose \< LLN then use \< 0.95\*pre-dose or \> ULN if pre-dose \> ULN then use \> 1.05\*pre-dose or \< LLN., Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)|Number of Treated Participants With Marked Abnormalities in Kidney and Liver Function Laboratory Tests, Blood urea nitrogen (BUN), milligrams/deciliter (mg/dL), units per liter (U/L). BUN mg/dL High: \> 1.5\*ULN; Creatinine mg/dL: \> 1.5\*ULN; Alanine aminotransferase (ALT) U/L: \> 3\*ULN; Aspartate aminotransferase (AST) U/L: \> 3\*ULN; Alkaline phosphatase U/L: \> 2\*ULN; Bilirubin Direct mg/dL: \> 1.5\*ULN; Bilirubin Total mg/dL: \> 2\*ULN., Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)|Number of Treated Participants With Marked Abnormalities in Creatine Kinase, Uric Acid, and Total Protein Laboratory Tests, Creatine kinase High: \>5\*ULN Units/Liter (U/L); Total Protein High/Low: \< 0.9 \*LLN or \> 1.1\*ULN, or if pre-dose \< LLN then use 0.9\* pre-dose or \> ULN if pre-dose \> ULN then use 1.1 \*pre-dose or \<LLN; Uric acid High: \> 1.5\* ULN, or if pre-dose \> ULN then use \> 2 \*pre-dose., Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)|Number of Treated Participants With Marked Abnormalities in Urinalysis Laboratory Tests, All tests in urine: Glucose: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Protein: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Blood: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Leukocyte esterase: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4;Red blood cells (RBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; White blood cells (WBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4., Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)",,Bristol-Myers Squibb,Pfizer,ALL,"ADULT, OLDER_ADULT",PHASE3,5614,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",CV185-056|EUDRACT: 2007-007867-25,2008-07,2013-03,2013-03,2008-03-26,2014-04-10,2014-04-21,"Alabama Clinical Therapeutics, Llc, Birmingham, Alabama, 35235, United States|Horizon Research Group, Inc., Mobile, Alabama, 36608, United States|Fort Smith Lung Center, Fort Smith, Arkansas, 72901, United States|University Of Arkansas For Medical Sciences, Little Rock, Arkansas, 72205, United States|Beaver Medical Group, Banning, California, 92220, United States|University Of California San Francisco-Fresno, Fresno, California, 93701, United States|University Of California, Davis Medical Center, Sacramento, California, 95817, United States|Chest Medicine & Critical Care Medical Gr. Inc., San Diego, California, 92123, United States|Stanford University Medical Center, Stanford, California, 94305, United States|Harbor Ucla Medical Center, Torrance, California, 90509, United States|New West Physicians, Golden, Colorado, 80401, United States|Drogue Medical, Llc, Wheat Ridge, Colorado, 80033, United States|Bridgeport Hospital, Bridgeport, Connecticut, 06610, United States|Dept Of Internal Med, Sect Of Pulmonary & Critical Care Med, New Haven, Connecticut, 06510, United States|George Washington University Medical Faculty Associates, Washington, District of Columbia, 20037, United States|Bay Pines Va Healthcare Systems, Bay Pines, Florida, 33744, United States|Daniel G. Lorch, Jr, Md, Cpi, Brandon, Florida, 33511, United States|Research Alliance, Inc., Clearwater, Florida, 33756, United States|River City Clinical Research, Jacksonville, Florida, 32207, United States|Pasadena Center For Medical Research, St. Petersburg, Florida, 33707, United States|Tampa Clinical Research, Tampa, Florida, 33624, United States|Office Of Michele S. Maholtz Md, Vero Beach, Florida, 32960, United States|Cleveland Clinic Florida, Weston, Florida, 33331, United States|Atlanta Pulmonary Group, Atlanta, Georgia, 30342, United States|Atlanta Institute For Medical Research, Inc, Decatur, Georgia, 30030, United States|Chatham Hospitalists, Savannah, Georgia, 31405, United States|Gateway Cardiology. P.C, Jerseyville, Illinois, 62052, United States|West Suburban Medical Center, Oak Park, Illinois, 60302, United States|Infectious Disease Of Indiana Psc, Carmel, Indiana, 46032, United States|Heartland Vascular Medicine And Surgery, Windsor Heights, Iowa, 50324, United States|Kentucky Lung Clinic, Hazard, Kentucky, 41701, United States|Univ. Of Kentucky Dept. Of Surgery, Lexington, Kentucky, 40536, United States|Research Integrity, Llc, Owensboro, Kentucky, 42303, United States|Pen Bay Medical Center, Rockport, Maine, 04856, United States|Anne Arundel Medical Center, Annapolis, Maryland, 21401, United States|R Adams Cowley Shock Trauma Center, Baltimore, Maryland, 21201, United States|Medstar Research Health Institute, Baltimore, Maryland, 21237, United States|Henry Ford Hospital, Detroit, Michigan, 48202, United States|Hurley Medical Center, Flint, Michigan, 48503, United States|Mississippi Medical Research, Llc, Picayune, Mississippi, 39466, United States|University Of Missouri-Columbia, Columbia, Missouri, 65212, United States|Veterans Affairs Medical Center, Kansas City, Missouri, 64128, United States|Washington University School Of Medicine, St Louis, Missouri, 63110, United States|St. John'S Mercy Medical Center, St. Louis, Missouri, 63141, United States|Mercury Street Medical Group, Pllc, Butte, Montana, 59701, United States|Great Falls Clinic, Llp, Great Falls, Montana, 59405, United States|Internal Medical Associates Of Grand Island, P.C, Grand Island, Nebraska, 68803, United States|Creighton University Medical Center, Omaha, Nebraska, 68131, United States|Morristown Memorial Hospital, Morristown, New Jersey, 07962, United States|Pulmonary & Critical Care Services, Pc, Albany, New York, 12205, United States|Kaleida Health System, Buffalo, New York, 14209, United States|Richmond University Medical Center, Staten Island, New York, 10310, United States|New York Medical College, Valhalla, New York, 10595, United States|Carolinas Medical Center, Charlotte, North Carolina, 28203, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States|Rex Healthcare, Raleigh, North Carolina, 27607, United States|Piedmont Healthcare/Research, Statesville, North Carolina, 28625, United States|Wilmington Medical Research, Wilmington, North Carolina, 28401, United States|Clinical Trials Of America, Inc., Winston Salem, North Carolina, 27103, United States|Altru Health System Clinic, Grand Forks, North Dakota, 58201, United States|Huron Hospital, Cleveland, Ohio, 44112, United States|Remington Davis Inc., Columbus, Ohio, 43215, United States|Oregon Health Science University, Portland, Oregon, 97239, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, 17033, United States|Greenville Hospital System, Greenville, South Carolina, 29615, United States|Palmetto Clinical Research, Summerville, South Carolina, 29485, United States|Holston Medical Group, Bristol, Tennessee, 37620, United States|Kore Cv Research, Jackson, Tennessee, 38305, United States|Primecare Medical Group, Houston, Texas, 77024, United States|Cancer Care Centers Of South Texas, San Antonio, Texas, 78229, United States|University Of Utah Medical Center, Salt Lake City, Utah, 84132, United States|Lake Washington Vascular, Pllc, Bellevue, Washington, 98004, United States|Franciscan Research Center, Tacoma, Washington, 98405, United States|Local Institution, Ciudad Autonoma De Buenos Aire, Buenos Aires, C1180AAX, Argentina|Local Institution, Rosario, Santa Fe, 2000, Argentina|Local Institution, Rosario, Santa Fe, S2000CVB, Argentina|Local Institution, Rosario, Santa Fe, S2000DSV, Argentina|Local Institution, Buenos Aires, C1280AEB, Argentina|Local Institution, Cordoba, 5000, Argentina|Local Institution, Corrientes, 3400, Argentina|Local Institution, Garran, Australian Capital Territory, 2605, Australia|Local Institution, Concord, New South Wales, 2139, Australia|Local Institution, Kogarah, New South Wales, 2217, Australia|Local Institution, Lismore, New South Wales, 2480, Australia|Local Institution, Randwick, New South Wales, 2031, Australia|Local Institution, Herston, Queensland, 4029, Australia|Local Institution, Adelaide, South Australia, 5000, Australia|Local Institution, Bedford Park, South Australia, 5042, Australia|Local Institution, Hobart, Tasmania, 7000, Australia|Local Institution, Box Hill, Victoria, 3128, Australia|Local Institution, Clayton, Victoria, 3168, Australia|Local Institution, Ringwood East, Victoria, 3135, Australia|Local Institution, Windsor, Victoria, 3181, Australia|Local Institution, Perth, Western Australia, 6001, Australia|Local Institution, Graz, 8036, Austria|Local Institution, Innsbruck, 6020, Austria|Local Institution, Vienna, 1090, Austria|Local Institution, Vienna, 1100, Austria|Local Institution, Vienna, 1140, Austria|Local Institution, Vienna, 1160, Austria|Local Institution, Wien, 1090, Austria|Local Institution, Belo Horizonte - Mg, Minas Gerais, 30150, Brazil|Local Institution, Curitiba, Parana, 80035, Brazil|Local Institution, Curitiba, Parana, 80050, Brazil|Local Institution, Curitiba, Parana, 80810, Brazil|Local Institution, Curitiba, Parana, 81520, Brazil|Local Institution, Rio Janeiro, Rio De Janeiro, 22280, Brazil|Local Institution, Port Alegre, Rio Grande Do Sul, 90020, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, 90035, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, 90110, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, 90610, Brazil|Local Institution, Botucatu, Sao Paulo, 18618, Brazil|Local Institution, Liberdade, Sao Paulo, 01509, Brazil|Local Institution, Sao Jose Do Rio Preto, Sao Paulo, 15090, Brazil|Local Institution, Sao Bernardo do Campo, SP, 09715, Brazil|Local Institution, Rio De Janeiro, 20551, Brazil|Local Institution, Sao Paulo, 01323, Brazil|Local Institution, Sao Paulo, 04005, Brazil|Local Institution, Sao Paulo, 04025, Brazil|Local Institution, Sao Paulo, 05403, Brazil|Local Institution, Edmonton, Alberta, T5H 4B9, Canada|Local Institution, Edmonton, Alberta, T6G 2B7, Canada|Local Institution, Vancouver, British Columbia, V5Z 1M9, Canada|Local Institution, Vancouver, British Columbia, V6Z 1Y6, Canada|Local Institution, Victoria, British Columbia, V8R 6R5, Canada|Local Institution, Winnipeg, Manitoba, R2H 2A6, Canada|Local Institution, Saint John, New Brunswick, E2L 4L2, Canada|Local Institution, Hamilton, Ontario, L8L 2X2, Canada|Local Institution, Hamilton, Ontario, L8N 4A6, Canada|Local Institution, Hamilton, Ontario, L8S 4K1, Canada|Local Institution, Ottawa, Ontario, K1Y 4E9, Canada|Local Institution, Toronto, Ontario, M5G 2C4, Canada|Local Institution, Waterloo, Ontario, N2J 1C4, Canada|Local Institution, Windsor, Ontario, N8X 5A6, Canada|Local Institution, Greenfield Park, Quebec, J4V 2H1, Canada|Local Institution, Montreal, Quebec, H1T 2M4, Canada|Local Institution, St. Jerome, Quebec, J7Z 5T3, Canada|Local Institution, Punta Arenas, Magallanes Antartica, 6212296, Chile|Local Institution, Independencia, Metropolitana, XXXXX, Chile|Local Institution, Santiago, Metropolitana, 7600448, Chile|Local Institution, Santiago, Metropolitana, 8330024, Chile|Local Institution, Vina Del Mar, Valparaiso, 2520000, Chile|Local Institution, Beijing, Beijing, 100020, China|Local Institution, Beijing, Beijing, 100029, China|Local Institution, Beijing, Beijing, 100032, China|Local Institution, Beijing, Beijing, 100035, China|Local Institution, Beijing, Beijing, 100037, China|Local Institution, Beijing, Beijing, 100038, China|Local Institution, Beijing, Beijing, 100053, China|Local Institution, Beijing, Beijing, 100191, China|Local Institution, Guangzhou, Guangdong, 510080, China|Local Institution, Wuhan, Hubei, 430022, China|Local Institution, Shengyang, Liaoning, 110004, China|Local Institution, Shanghai, Shanghai, 200032, China|Local Institution, Shanghai, Shanghai, 200127, China|Local Institution, Hangzhou, Zhejiang, 130016, China|Local Institution, Hangzhou, Zhejiang, 310016, China|Local Institution, Xian, 710032, China|Local Institution, Hradec Kralove, 500 05, Czech Republic|Local Institution, Kladno, 272 59, Czech Republic|Local Institution, Litomysl, 570 14, Czech Republic|Local Institution, Mestec Kralove, 289 03, Czech Republic|Local Institution, Ostrava Vitkovice, 703 84, Czech Republic|Local Institution, Ostrava, 708 52, Czech Republic|Local Institution, Praha 10, 100 34, Czech Republic|Local Institution, Praha 1, 110 00, Czech Republic|Local Institution, Praha 1, 118 33, Czech Republic|Local Institution, Praha 2, 128 08, Czech Republic|Local Institution, Usti Nad Labem, 401 13, Czech Republic|Local Institution, Usti Nad Orlici, 562 18, Czech Republic|Local Institution, Arhus C, 8000, Denmark|Local Institution, Hellerup, 2900, Denmark|Local Institution, Herning, 7400, Denmark|Local Institution, Hilleroed, 3400, Denmark|Local Institution, Horsens, 8700, Denmark|Local Institution, Naestved, 4700, Denmark|Local Institution, Silkeborg, 8600, Denmark|Local Institution, Angers, 49000, France|Local Institution, Arras, 62022, France|Local Institution, Besancon, 25000, France|Local Institution, Clamart, 92141, France|Local Institution, Clermont-Ferrand Cedex 01, 63003, France|Local Institution, Dijon, 21079, France|Local Institution, Grenoble Cedex 9, 38043, France|Local Institution, Langres Cedex, 52206, France|Local Institution, Le Kremlin-Bicetre, 94275, France|Local Institution, Lille Cedex, 59020, France|Local Institution, Limoges Cedex, 87042, France|Local Institution, Nantes, 44093, France|Local Institution, Paris, 75004, France|Local Institution, Paris, 75010, France|Local Institution, Pierre Benite, 69495, France|Local Institution, Saint-Priest En Jarez, 42270, France|Local Institution, Toulouse cedex 9, 31059, France|Local Institution, Vernon, 27200, France|Local Institution, Berlin, 10117, Germany|Local Institution, Berlin, 10787, Germany|Local Institution, Berlin, 12559, Germany|Local Institution, Berlin, 14050, Germany|Local Institution, Bochum, 44791, Germany|Local Institution, Cologne, 50937, Germany|Local Institution, Dortmund, 44137, Germany|Local Institution, Dresden, 01067, Germany|Local Institution, Dresden, 01307, Germany|Local Institution, Frankfurt, 60596, Germany|Local Institution, Gottingen, 37075, Germany|Local Institution, Karlsbad, 76307, Germany|Local Institution, Ludwigshafen, 67063, Germany|Local Institution, Mannheim, 68161, Germany|Local Institution, Mannheim, 68163, Germany|Local Institution, Munchen, 80331, Germany|Local Institution, Munich, 80336, Germany|Local Institution, Pokfulman, XXXXX, Hong Kong|Local Institution, Shatin, N.T, Hong Kong|Local Institution, Budapest, 1032, Hungary|Local Institution, Budapest, 1097, Hungary|Local Institution, Budapest, 1125, Hungary|Local Institution, Gyula, 5700, Hungary|Local Institution, Kecskemet, 6000, Hungary|Local Institution, Miskolc, 3501, Hungary|Local Institution, Mosonmagyarovar, 9200, Hungary|Local Institution, Szekesfehervar, 8000, Hungary|Local Institution, Zalaegerszeg, 8900, Hungary|Local Institution, Hyderabad, Andhra Pradesh, 500 082, India|Local Institution, Hyderabad, Andhra Pradesh, 500034, India|Local Institution, Ahmedabad, Gujarat, 380006, India|Local Institution, Gurgaon, Haryana, 122001, India|Local Institution, Bangalore, Karnataka, 560054, India|Local Institution, Bengaluru, Karnataka, 560017, India|Local Institution, Manipal, Karnataka, 576104, India|Local Institution, Pune, Maharashtra, 411001, India|Local Institution, Mohali, Punjab, 160062, India|Local Institution, Ludhiana, Tagore Nagar, 141001, India|Local Institution, Chennai, Tamil Nadu, 600 006, India|Local Institution, Bangalore, 560052, India|Local Institution, Bangalore, 560099, India|Local Institution, Pune, 411001, India|Local Institution, Tiberias, Lower Galillee, 15208, Israel|Local Institution, Afula, 18101, Israel|Local Institution, Ashkelon, 78278, Israel|Local Institution, Hadera, 38101, Israel|Local Institution, Haifa, 31048, Israel|Local Institution, Haifa, 31096, Israel|Local Institution, Holon, 58100, Israel|Local Institution, Jerusalem, 91031, Israel|Local Institution, Jerusalem, 91120, Israel|Local Institution, Kfar Saba, 44281, Israel|Local Institution, Nahariya, 22100, Israel|Local Institution, Petach-Tikva, 49100, Israel|Local Institution, Rehovot, 76100, Israel|Local Institution, Safed, 13100, Israel|Local Institution, Tel Aviv, 64239, Israel|Local Institution, Tel Hashomer, 52621, Israel|Local Institution, Bologna, 40138, Italy|Local Institution, Castelfranco Veneto (Tv), 31033, Italy|Local Institution, Chieti Scalo, 66013, Italy|Local Institution, Cosenza, 87100, Italy|Local Institution, Milano, 20132, Italy|Local Institution, Padova, 35128, Italy|Local Institution, Palermo, 90127, Italy|Local Institution, Pavia, 27100, Italy|Local Institution, Piacenza, 29100, Italy|Local Institution, Pisa, 56124, Italy|Local Institution, Reggio Emilia, 42100, Italy|Local Institution, Rome, 00168, Italy|Local Institution, Rozzano (Mi), 20089, Italy|Local Institution, San Daniele Del Friuli (Ud), 33038, Italy|Local Institution, Vicenza, 36100, Italy|Local Institution, Vittorio Veneto (Tv), 31029, Italy|Local Institution, Busan, 602-702, Korea, Republic of|Local Institution, Seoul, 120752, Korea, Republic of|Local Institution, Seoul, 137-040, Korea, Republic of|Local Institution, Seoul, 138736, Korea, Republic of|Local Institution, Georgetown, Penang, 10350, Malaysia|Local Institution, Ipoh, Perak, 30990, Malaysia|Local Institution, Kuala Lumpur, 50586, Malaysia|Local Institution, Melaka, 75400, Malaysia|Local Institution, Tijuana, Baja California, 22500, Mexico|Local Institution, Leon, Guanajuato, 37320, Mexico|Local Institution, Guadalajara, Jalisco, 44280, Mexico|Local Institution, Zapopan, Jalisco, 45170, Mexico|Local Institution, Zapopan, Jalisco, 45200, Mexico|Local Institution, Monterrey, Nuevo Leon, 64000, Mexico|Local Institution, Monterrey, Nuevo Leon, 64718, Mexico|Local Institution, Xalapa, Veracruz, 91020, Mexico|Local Institution, Aguascalientes, 20230, Mexico|Local Institution, Durango, 34080, Mexico|Local Institution, Alesund, 6017, Norway|Local Institution, Fredrikstad, 1606, Norway|Local Institution, Gjettum, 1346, Norway|Local Institution, Gjovik, 2819, Norway|Local Institution, Hamar, 2318, Norway|Local Institution, Oslo, 0319, Norway|Local Institution, Oslo, 0407, Norway|Local Institution, Oslo, 0456, Norway|Local Institution, Trondheim, 7006, Norway|Local Institution, Tynset, 2500, Norway|Local Institution, Bialystok, 15-276, Poland|Local Institution, Bydgoszcz, 85-168, Poland|Local Institution, Bydgoszcz, 85-681, Poland|Local Institution, Gdansk, 80-803, Poland|Local Institution, Gdynia, 81-348, Poland|Local Institution, Lodz, 90-153, Poland|Local Institution, Lublin, 20-081, Poland|Local Institution, Lublin, 20-718, Poland|Local Institution, Poznan, 61-848, Poland|Local Institution, Przeworsk, 37-200, Poland|Local Institution, Szczecin, 70-111, Poland|Local Institution, Warsawa, 02-776, Poland|Local Institution, Warsaw, 02-005, Poland|Local Institution, Warszawa, 01-138, Poland|Local Institution, Wroclaw, 50-981, Poland|Local Institution, Wroclaw, 51-124, Poland|Local Institution, Coimbra, 3004-548, Portugal|Local Institution, Guarda, 6301-857, Portugal|Local Institution, Lisboa, 1169-050, Portugal|Local Institution, Lisboa, 1769-001, Portugal|Local Institution, San Juan, 00921, Puerto Rico|Local Institution, Baia Mare, 430031, Romania|Local Institution, Bucharest, 022328, Romania|Local Institution, Bucharest, 030171, Romania|Local Institution, Bucharest, 050098, Romania|Local Institution, Targu Mures, 540136, Romania|Local Institution, Arkhangelsk, 163045, Russian Federation|Local Institution, Chelyabinsk, 454136, Russian Federation|Local Institution, Kazan, 420101, Russian Federation|Local Institution, Moscow, 109386, Russian Federation|Local Institution, Moscow, 111539, Russian Federation|Local Institution, Moscow, 115093, Russian Federation|Local Institution, Moscow, 115280, Russian Federation|Local Institution, Moscow, 117292, Russian Federation|Local Institution, Moscow, 119049, Russian Federation|Local Institution, Moscow, 121359, Russian Federation|Local Institution, Moscow, 121552, Russian Federation|Local Institution, Moscow, 127473, Russian Federation|Local Institution, Novosibirsk, 630090, Russian Federation|Local Institution, Rostov-On Don, 344022, Russian Federation|Local Institution, Ryazan, 390026, Russian Federation|Local Institution, Saint Petersburg, 192242, Russian Federation|Local Institution, Saint Petersburg, 197022, Russian Federation|Local Institution, Saint-Petersburg, 196247, Russian Federation|Local Institution, Saint-Petersburg, 197341, Russian Federation|Local Institution, Saint-Petersburg, 199106, Russian Federation|Local Institution, Saratov, 410012, Russian Federation|Local Institution, St Petersburg, 194044, Russian Federation|Local Institution, Yaroslavl, 150062, Russian Federation|Local Institution, Singapore, 169608, Singapore|Local Institution, Singapore, 308433, Singapore|Local Institution, Singapore, 529889, Singapore|Local Institution, Bioemfontein, Free State, 9301, South Africa|Local Institution, Centurion, Gauteng, 0157, South Africa|Local Institution, Parktown, Gauteng, 2193, South Africa|Local Institution, Pretoria, Gauteng, 0084, South Africa|Local Institution, Durban, Kwa Zulu Natal, 4001, South Africa|Local Institution, Pietermaritzburg, Kwa Zulu Natal, 3201, South Africa|Local Institution, Bellville, Western Cape, 7530, South Africa|Local Institution, George, Western Cape, 6529, South Africa|Local Institution, Somerset West, Western Cape, 7130, South Africa|Local Institution, Worcester, Western Cape, 6850, South Africa|Local Institution, Torrevieja, Alicante, 03186, Spain|Local Institution, Getafe, 28905, Spain|Local Institution, L'Hospitalet De Llobregat, 08907, Spain|Local Institution, Leon, 24008, Spain|Local Institution, Madrid, 28007, Spain|Local Institution, Madrid, 28029, Spain|Local Institution, Madrid, 28041, Spain|Local Institution, Malaga, 29010, Spain|Local Institution, Mourente, 36071, Spain|Local Institution, Tarragona, 43007, Spain|Local Institution, Chernihiv, 14034, Ukraine|Local Institution, Dnipropetrovsk, 49000, Ukraine|Local Institution, Donetsk, 83045, Ukraine|Local Institution, Ivano-Frankivsk, 76008, Ukraine|Local Institution, Ivano-Frankivsk, 76018, Ukraine|Local Institution, Kharkiv, 61018, Ukraine|Local Institution, Kyiv, 03680, Ukraine|Local Institution, Lviv, 79010, Ukraine|Local Institution, Odesa, 65117, Ukraine|Local Institution, Ternopil, 46000, Ukraine|Local Institution, Vinnytsia, 21018, Ukraine|Local Institution, Zaporizhzhia, 69035, Ukraine|Local Institution, Livingston, West Lothian, EH54 7BH, United Kingdom",
